Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs. But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s. That became clear last week after the pair reported their respective second-quarter earnings. "Lilly is pu ...